These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17539056)

  • 1. Lisdexamfetamine dimesylate.
    Elia J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 May; 6(5):343-4. PubMed ID: 17539056
    [No Abstract]   [Full Text] [Related]  

  • 2. Sex subgroup analysis of treatment response to lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder.
    McGough JJ; Greenbaum M; Adeyi B; Babcock T; Scheckner B; Dirks B; Findling RL
    J Clin Psychopharmacol; 2012 Feb; 32(1):138-40. PubMed ID: 22217951
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment].
    't Jong GW; van den Anker JN
    Ned Tijdschr Geneeskd; 2000 Nov; 144(46):2227-8. PubMed ID: 11103263
    [No Abstract]   [Full Text] [Related]  

  • 7. An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.
    Wigal SB; Raja P; Shukla A
    Expert Opin Pharmacother; 2013 Jan; 14(1):137-45. PubMed ID: 23241144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
    Brams M; Giblin J; Gasior M; Gao J; Wigal T
    Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity disorder: the road traveled and the road ahead.
    Jun A
    Am J Health Syst Pharm; 2009 Nov; 66(22):2003. PubMed ID: 19890082
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecule of the month: lisdexamfetamine mesilate.
    Drug News Perspect; 2007 Mar; 20(2):138. PubMed ID: 17440637
    [No Abstract]   [Full Text] [Related]  

  • 15. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Jun; (7):262-71. PubMed ID: 12230649
    [No Abstract]   [Full Text] [Related]  

  • 16. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
    Waxmonsky JG; Waschbusch DA; Glatt SJ; Faraone SV
    J Clin Psychiatry; 2011 Oct; 72(10):1366-75. PubMed ID: 21367347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
    Mattingly G
    CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human subjects research. Pediatric study of ADHD drug draws high-level public review.
    Couzin J
    Science; 2004 Aug; 305(5687):1088-9. PubMed ID: 15326317
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.